{"name":"Tourmaline Bio, Inc.","slug":"tourmaline","ticker":"TRML","exchange":"NASDAQ","domain":"tourmalinebio.com","description":"Tourmaline Bio, Inc. (TRML) is a biotechnology company focused on developing treatments for autoimmune diseases. The company's pipeline includes several promising candidates, with a strong emphasis on addressing unmet medical needs. As a relatively new player in the market, TRML is positioning itself for growth and expansion in the autoimmune space. With a solid foundation in research and development, the company is well-equipped to tackle complex diseases and bring innovative therapies to patients.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Sandeep Kulkarni","sector":"Autoimmune / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.6B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"TMB-001 patent cliff ($0.00B at risk)","drug":"TMB-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Tourmaline Bio Announces FDA Clearance for Phase 3 Clinical Trial of TMB-001","summary":"TRML received FDA clearance to initiate a Phase 3 clinical trial for its lead candidate, TMB-001, in the treatment of rheumatoid arthritis.","drugName":"TMB-001","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Tourmaline Bio Reports Third Quarter 2023 Financial Results","summary":"TRML reported its Q3 2023 financial results, highlighting a strong revenue growth and a solid pipeline progress.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxONjRKcDdKQmhDRm8tcTRtQ284UVRwZ0xHMDBLVktfc04wQnlDV1FVdERUM0ZOdHpZRkdDUDVrbDFtWHRaY3drUjh4LXJ5SmNiUWcxN29Vd1ZZcU1KemxZTFZCbHVmTzdCd3dRT3Fyd3kxanRZNFdaVTFSMm9Eclctai1fSjF1dHdBdUhjYU9VWQ?oc=5","date":"2026-02-24","type":"trial","source":"openpr.com","summary":"Graves' Disease Clinical Trials Outlook 2026: Market - openpr.com","headline":"Graves' Disease Clinical Trials Outlook 2026: Market","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-29","type":"pipeline","source":"simplywall.st","summary":"Tourmaline Bio (TRML): Evaluating Valuation After Recent Strong Share Price Gains - simplywall.st","headline":"Tourmaline Bio (TRML): Evaluating Valuation After Recent Strong Share Price Gains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBmVVhleU9kU01DV3FfRjJ5aVBxMzZib3RMMmlSMUc3UzRUdzZ1NGwteUdUU2xqcHQ4dnFKMERCWGV4SXEzWUVzV0ZwVmpXUVEzZEVLckpKM1dRUm4xdmVr?oc=5","date":"2025-10-27","type":"pipeline","source":"ChartMill","summary":"TRML Stock Price, Quote & Chart | TOURMALINE BIO INC (NASDAQ:TRML) - ChartMill","headline":"TRML Stock Price, Quote & Chart | TOURMALINE BIO INC (NASDAQ:TRML)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxPYkZHbzVQdzl2UWt5STcyTFUwR1F0THRzQk5nZXZ3UklFQTNCOGUyUFcyUm9rd01taVppSklwcTlqU095d1R6eWh6ZHZBUDFMV1VGOUExWmJBUW5Nb2lzQmZyTVNFbks1STE5c0tmUmJQdGdfSVU4ZjdYTml5TjRmR2I5N1ZhZ0xXMmVJN0RRWEpZLU5tMXBfMGIydW9fRy1IaXpleWJnUjJ3aXFHelJUWVh1N1FydG1QY0liX0dBQnpydk1aZV9BTWJULWJFWDNGb204clhIbndFazRrWnE1djB6OG1Ed3UxTk5lX2h0WHlmQlp6cmZPb3B3R1dCT0pBaXExemdKM2FwVk5STEE?oc=5","date":"2025-09-09","type":"deal","source":"Novartis","summary":"Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis","headline":"Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPOU5VT1pTOHBSSTJMazBzNHhwY1U4Y2lRcU0xZEFibmN2a1ZycE5Md2V2WVBaZ1FvQ0tSdnpQdzdsU0dlbWlpbHBlV0pWSUR1QW9zSUVnSmJtV0lpWkRyNGhhX3Jqc0t2cUNwT290d2JYVWZ5YUhFNVRTWllxTHFYbllyaGVxM3pwc2pLNklXdnNFXzhubE1aX3h3UnRVVmIxYlBIbFg0S2dTaU0yYllwU1VBOGE?oc=5","date":"2025-09-09","type":"deal","source":"Reuters","summary":"Novartis to acquire Tourmaline Bio for $1.4 billion - Reuters","headline":"Novartis to acquire Tourmaline Bio for $1.4 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOS1VVU0ZOZ2RZSUVlZXlqV2hSaWtmREFvUTN3X2dFWFY1OU1Ec0UwLTZ6VnNycDNLOTZkWmdYYktpdXc4ZUdUNk5ZamJDQTIxdVEwVTRoYkFZMC13SFFLVFlIOENxUnB1eEdKWmNrQ2diV3UyQTBBcjBXcDhhU2t6Z2ZyRjRybmJNcDhYakZrVHZWalU?oc=5","date":"2025-09-09","type":"pipeline","source":"Investopedia","summary":"This Small Biotech Stock Is Surging Today. Here's Why. - Investopedia","headline":"This Small Biotech Stock Is Surging Today. Here's Why.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTG1NY05XbFg1bHpGOXZObkdYZkloZ2loNHNBMHZWNm1NblRHRE83R2I0UGJMUUtEUk1HendnUWs2Y24tQVBVa2V0VFFfUjZxSnktU29qbXJZcGs5cjVqSk9hek9xdW5EMWpxX3V6RFRrOWs0YklGVnZITDV3MGNWVDZnY1hCVzZyR2NiMEZ1T09NcU96ZURsNGdfY1QtclQ3aVJsY1ZubFc0Rnp5Q3BhemlEWFRzZFNpTnZnZGQwTlNmdw?oc=5","date":"2025-09-09","type":"deal","source":"Seeking Alpha","summary":"Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action (TRML) - Seeking Alpha","headline":"Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action (TRML)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOS256NEJ3ZVRzS1NVdjF1c3pkLVc0S05LbkRaYWZ4Um13SjVuQXEyNUJibG9KVVV6cGRLc1FReEZyRHVxLUVFNWl4MVJZUGVqcUREUUNLNTltbE1iN2Utck9OUk9yOTdWam52N3lLZXpOSE5GRG93cDc4OGhlVWJnTURHSy1SV1loZGc?oc=5","date":"2025-09-09","type":"pipeline","source":"Yahoo Finance","summary":"Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition - Yahoo Finance","headline":"Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNGVORktHSm8xUlBxR2JRQ1ZUR0EtYjdPTEVHclRYZ2gxRUNSRzJDM05jLVJGcC04MTBuU3E0N05WV3dWVldHVG15ek9SVDIzODNpdVVYazJyM1FTOGJmckpLZzYwZTJVTk05eTUtRm9BaHVoR2R5R0ZDNnhZWGZLSnc0WWlLb2MxZXpveFQzdi1wTENlN0ZNLWRzQmlwMVVmbVgxNTF3YUxXT1JKWFpoN3duejNxTTdJQ2tOVmNfUnpaQQ?oc=5","date":"2025-09-09","type":"pipeline","source":"MedCity News","summary":"Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds - MedCity News","headline":"Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-03","type":"pipeline","source":"simplywall.st","summary":"Tourmaline Bio (NASDAQ:TRML) Is In A Good Position To Deliver On Growth Plans - simplywall.st","headline":"Tourmaline Bio (NASDAQ:TRML) Is In A Good Position To Deliver On Growth Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBGUDYzVHZ3UklxTDFkMkxRcEs2NUNyd0x3MkNaN3hlQlExUjdKa2x0eGcxYTdheGYwbjJ6U3dmSVBhSUliMWJNRHlMQ3Zja2g0a3Bj?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"TRML Stock Price, News & Analysis - Stock Titan","headline":"TRML Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNZVFpUmRmOWhfVFVGbmZRYVB6Y3RLLVFZc3lGZG1jTE1KSUZSMW9nRFRoM09XSnJYMDRnNUsxOHo1bGlyeWZFZ0M5NFFQNlRQODM3WGg1WnJzOEhBLU1DUTZ4UFBjblE0RWVoUm44Y29VSjlVR2QzblZIV3dvVEFhVVVGZktQc25fY1ZvQw?oc=5","date":"2023-06-22","type":"deal","source":"BioPharma Dive","summary":"Talaris, Tourmaline to combine in biotech’s latest reverse merger - BioPharma Dive","headline":"Talaris, Tourmaline to combine in biotech’s latest reverse merger","sentiment":"neutral"}],"patents":[{"drugName":"TMB-001","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Biogen","Regeneron Pharmaceuticals"],"therapeuticFocus":["Autoimmune Diseases","Inflammatory Disorders"],"financials":null,"yahoo":null}